<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied 48 patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease to determine the clinical spectrum of the disease </plain></SENT>
<SENT sid="1" pm="."><plain>We also compared the seropositivity of patients for <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B (HBV) and C (HCV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> with a healthy control group to determine whether there is an association </plain></SENT>
<SENT sid="2" pm="."><plain>The major physical findings were oral <z:e sem="disease" ids="C0016514" disease_type="Disease or Syndrome" abbrv="">aphthosis</z:e> 93.8%, genital <z:e sem="disease" ids="C0016514" disease_type="Disease or Syndrome" abbrv="">aphthosis</z:e> 77.1% and ocular manifestations 64.6% </plain></SENT>
<SENT sid="3" pm="."><plain>No patients were HCV antibody seropositive, but 3 of the control group (3.1%) tested seropositive </plain></SENT>
<SENT sid="4" pm="."><plain>One patient (2.1%) and 2 in the control group (2.1%) tested positive for both HBV surface antigen and HBV core antibody </plain></SENT>
<SENT sid="5" pm="."><plain>The differences were not statistically significant </plain></SENT>
<SENT sid="6" pm="."><plain>There is, therefore, no case for recommending <z:mp ids='MP_0001799'>viral</z:mp> screening for HBV and HCV in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease patients at present </plain></SENT>
</text></document>